Handbook of Lymphoma

Introduction.- Risk factors, etiology, and pathogenesis.- World Health Organization classification.- Staging.- Treatment overview.- Treatment of B-cell lymphomas.- Treatment of T-cell lymphomas.- Treatment of Hodgkin lymphoma.- Management of human immunodeficiency virus-associated lymphomas

The Handbook of Lymphoma is an in-depth and comprehensive guide to the diagnosis, staging, treatment, and management of patients with the disease. The Handbook aims to provide healthcare professionals with an informative and up-to-date guide to the latest developments in the treatment of patients with both Hodgkin and non-Hodgkin lymphoma. Lymphoma is a cancer of the lymphatic system and, as with other cancers, is a disease of the body's cells. Usually, cells divide in the body in an orderly and controlled manner, however when this process gets out of control and the cells carry on dividing in an abnormal manner a tumor can form known as lymphoma in one or more groups of lymph nodes. This field has seen increasing development in the available options for treating patients with lymphoma particularly in the recent emergence and approval of targeted therapies. In this clinically focused Handbook, the authors address these advances by looking at treatment recommendations for both Hodgkin and non-Hodgkin lymphoma, and also making suggestions on the future outlook for patients with this disease. This Handbook is an invaluable and educational source of topical information for all medical and healthcare professionals with an interest in lymphoma.

Author Information

Anas Younes, MD, is the Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College, New York, NY, USA. He has extensive experience in clinical and translational research in lymphoma. He was the Principal Investigator of the MD Anderson Cancer Center Lymphoma SPORE grant, and is currently the Principal Investigator of the Memorial Sloan Kettering Cancer Center Lymphoma SPORE grant. He has lead more than 60 clinical trials in lymphoma. He has lead, in collaboration with colleagues from around the world, the pivotal trials that resulted in the US FDA approval of brentuximab vedotin and nivolumab for the treatment of patients with relapsed Hodgkin lymphoma. He has published more than 250 papers on lymphoma.